Please provide your email address to receive an email when new articles are posted on . Postmenopausal women with osteoporosis who received a regimen of three separate, 6-month cycles of daily ...

Denosumab (Prolia, Amgen, Inc) does not appear to delay fracture healing or cause other complications when given at or near the time of fracture in postmenopausal women with osteoporosis, according to ...

Many women on dialysis quickly developed severe hypocalcemia after starting denosumab (Prolia) for osteoporosis, Medicare data showed. During the first 12 weeks of treatment, 41.1% of women on ...

Please provide your email address to receive an email when new articles are posted on . A twice-yearly injection of denosumab improved spinal bone mineral density among individuals with osteoporosis ...

The U.S. Food and Drug Administration (FDA) approved the expanded indication of Prolia for the treatment of osteoporosis associated with newly initiating or sustained systemic glucocorticoid therapy ...

November 10, 2010 — In advanced breast cancer patients who have bone metastases, the novel biologic denosumab was superior to zoledronic acid in preventing skeletal-related events (SREs) and renal ...

"Today's positive opinion by the CHMP is an important step for Prolia in helping patients suffering from bone loss associated with systemic glucocorticoid therapy," said Sean E. Harper, M.D., ...

Denosumab significantly reduced fractures in postmenopausal women with breast cancer receiving aroma The medication inhibits bone resorption but is associated with prolonged elevation in PTH levels ...

Phosphorus, Calcium Decreases Linked to Improved HD Patient Survival A biological link between bone metabolism and vascular calcification has long been hypothesized. Denosumab, an osteoporosis drug, ...

Correcting for Discretionary Treatment Crossover in an Analysis of Survival in the Breast International Group BIG 1-98 Trial by Using the Inverse Probability of Censoring Weighted Method Bone ...

JERSEY CITY, N.J., March 4, 2025 /PRNewswire/ -- Celltrion today announced that the U.S. Food and Drug Administration (FDA) has approved STOBOCLO ® (CT-P41, denosumab-bmwo) and OSENVELT ® (CT-P41, ...

BENGALURU, India and BRIDGEWATER, N.J., Sept. 17, 2025 /PRNewswire/ -- Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of ...